Compare NABL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | GERN |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.6M | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | NABL | GERN |
|---|---|---|
| Price | $3.56 | $1.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $8.31 | $2.17 |
| AVG Volume (30 Days) | 1.1M | ★ 15.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $511,430,000.00 | N/A |
| Revenue This Year | $11.04 | $26.91 |
| Revenue Next Year | $8.53 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $3.24 | $1.04 |
| 52 Week High | $9.04 | $2.01 |
| Indicator | NABL | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 30.88 |
| Support Level | N/A | $1.24 |
| Resistance Level | $5.22 | $1.29 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | -0.21 | -0.03 |
| Stochastic Oscillator | 13.21 | 4.04 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.